Tirzepatide Slashed Predicted 10-Year Diabetes Risk from 5% to 1% in Overweight Chinese Adults

What the researchers found

In the SURMOUNT-CN trial post hoc analysis (n=169), tirzepatide 10 mg reduced predicted 10-year T2D risk from 5.3% to 1.2%, and 15 mg from 4.9% to 1.0%, compared to placebo (5.8% to 4.5%) at week 52. The LS mean risk reductions versus placebo were -3.2% (95% CI: -4.2% to -2.2%) for 10 mg and -3.4% (95% CI: -4.4% to -2.4%) for 15 mg. Significantly greater reductions were observed across all subgroups regardless of baseline BMI status or prediabetes status.

Why it matters

Diabetes prevention is a major public health goal, especially in Asian populations where diabetes risk increases at lower BMI thresholds. This analysis demonstrates that tirzepatide doesn't just help with weight loss — it fundamentally alters the metabolic trajectory, reducing predicted diabetes risk by approximately 75-80%. This supports the case for using GIP/GLP-1 dual agonists as diabetes prevention tools.

How the study worked

This was a post hoc analysis of the SURMOUNT-CN randomized controlled trial. Researchers used the QDiabetes-2018 risk engine to calculate predicted 10-year T2D risk at baseline, week 24, and week 52 for participants randomized to tirzepatide 10 mg (n=59), 15 mg (n=53), or placebo (n=57). A mixed model for repeated measures compared risk changes between groups, with subgroup analyses by BMI and prediabetes status.

What this study cannot tell us

This is a post hoc analysis, not a pre-specified endpoint of the trial. The predicted T2D risk was calculated using a risk engine (QDiabetes-2018) rather than measuring actual diabetes incidence. The sample size is small (169 participants total). The 52-week timeframe does not capture what happens after medication is stopped. The QDiabetes tool was developed for a UK population and may not be perfectly calibrated for Chinese populations.

How to read the evidence

This is a post hoc analysis of a randomized controlled trial, which provides moderate evidence. While the underlying RCT data is strong, the post hoc nature, use of a predicted risk model rather than actual diabetes incidence, and small sample size moderate the certainty of conclusions.

When this study was published

Published in 2025, this analysis provides timely data on tirzepatide's metabolic benefits specifically in a Chinese population, relevant as the drug becomes available in Asian markets.

The bigger picture

Tirzepatide is the first GIP/GLP-1 dual agonist peptide, and this analysis from a China-specific trial extends its metabolic benefits to an East Asian population. As diabetes rates surge across Asia, demonstrating that tirzepatide can dramatically reduce diabetes risk in this population is clinically and commercially significant. The data also supports the broader concept of using incretin-based peptide therapies for disease prevention, not just treatment.

Questions still open

• Does the reduced predicted diabetes risk translate to actual reduced diabetes incidence over 10 years?
• Is the diabetes prevention effect maintained after tirzepatide is discontinued?
• Should tirzepatide be considered as a standard diabetes prevention therapy in high-risk overweight Asian populations?

Common questions

Read the original research

Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.

Diabetes, obesity & metabolism, 27(8), 4118-4125

Citation

Zhao, Lin; Tao, Feng; Cheng, Zhifeng; Lu, Yibing; Liu, Ming; Chen, Hong; Zhang, Min; Yang, Yang; Song, Xiang; Sun, Yuzi; Ma, Xiao; Si, Si; Zhang, Hanxi; Li, Xiaoying. (2025). Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.. Diabetes, obesity & metabolism, 27(8), 4118-4125. https://doi.org/10.1111/dom.16439